NHKI - Drug Therapies

Ongoing Studies

• Antibiotics
  BALANCE+
  

  • BALANCE +: A Platform Trial for Gram Negative Bloodstream Infections
  • This study will assess multiple treatment options for bloodstream infections caused by Gram Negative bacteria that lead to hospitalization.

  REMAP-CAP

  • REMAP-CAP: Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Patients with Community Acquired Pneumonia
  • Community acquired pneumonia that is severe enough to require admission to an ICU will often receive many different treatments as many as 20 or 30. These treatments act together to treat both the infection and its effect on the body. This study aims to help doctors understand which treatment options are best.
  • Antibiotic Domain: will compare use of up to 5 antibiotic interventions.

  SNAP

  • SNAP: Staphylococcus Aureus Network Adaptive Platform Trial
  • Bloodstream infections caused by the bacterium Staphylococcus aureus (Staphylococcus aureus bacteraemia, SAB) can be deadly. While there are many treatment options in current use, there is no clear agreement as to which of these is best. This trial aims to identify which treatment options are best.
• Anticoagulants and antithrombotics

  ANT-010 (LILAC-TIMI)

  • LILAC-TIMI 76: Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High-risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagulation
  • This study evaluates the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with atrial fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

  ASPIRE-AF

  • ASPIRE-AF: Anticoagulation for Stroke Prevention in Patients with Recent Episodes of Perioperative Atrial Fibrillation after Noncardiac Surgery
  • This study investigates the use of oral anticoagulation vs. no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient perioperative atrial fibrillation after noncardiac surgery and additional stroke risk factors.

  ATTACC-CAP

  • ATTACC-CAP: Anti-thrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
  • Community Acquired Pneumonia (CAP) is a life-threatening lung infection and a leading cause of hospitalization and mortality globally. Poor clinical outcomes are driven by the inappropriate response of the body’s inflammatory and thrombotic systems to infection, leading to thrombosis and organ dysfunction. This trial will determine if a therapeutic-dose anticoagulation with heparin will improve clinical outcomes in non-critically ill hospitalized patients.

  TRIM-Line

  • TRIM-Line: Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
  • The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent blood clots (venous thromboembolism) among cancer patients with central venous catheters.
• Anti-inflammatory drugs

  LEADER-PAD

  • LEADER-PAD: Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
  • This study will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.

  PRACTICAL: Fast 3 Domain

  • PRACTICAL: Platform of Randomized Adaptive Clinical Trials in Critical Illness
  • This platform trial evaluates novel interventions for patients with acute hypoxemic respiratory failure (AHRF).
• Anti-hypotensive drugs

  CEPEC: OptiMAP Domain

  • CEPEC: Canadian Critical Care Comparative Effectiveness Platform
  • This adaptive platform trial will evaluate the clinical effectiveness of supportive care interventions that are routinely used in the ICU.
  • The OptiMap Domain evaluates different target ranges of mean arterial pressure (MAP) for patients on vasopressors

  LIBERATE

  • LIBERATE: Midodrine for the Early Liberation of Vasopressor Support in the ICU
  • Patients in the ICU often need medications called vasopressors to help maintain their blood pressure. However, using these strong IV medications for too long can have risks. This study will explore whether midodrine, a blood pressure medication taken orally, can help reduce the need for IV vasopressors as patients recover in the ICU.
• Corticosteroids

  PRACTICAL: CORT E2 Domain

  • PRACTICAL: Platform of Randomized Adaptive Clinical Trials in Critical Illness
  • This platform trial evaluates novel interventions for patients with acute hypoxemic respiratory failure (AHRF).
  • The CORT-E2 Trial is a phase III multicenter RCT investigating early corticosteroids versus no extension in persistent acute hypoxemic respiratory failure (AHRF) from COVID or non-COVID causes.

  REMAP-CAP

  • REMAP-CAP: Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Patients with Community Acquired Pneumonia
  • Community acquired pneumonia that is severe enough to require admission to an ICU will often receive many different treatments as many as 20 or 30. These treatments act together to treat both the infection and its effect on the body. This study aims to help doctors understand which treatment options are best.
  • Corticosteroid Domain: will compare the following interventions: no corticosteroid administration, fixed duration hydrocortisone for 7 days and shock-dependent hydrocortisone while the patient is in septic shock.
• Oncology drugs

  CRC.10 (CIRCULATE NORTH AMERICA)

  • CIRCULATE-NORTH AMERICA: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  • This study will evaluate what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA after surgery for colon cancer.

  MY.13

  • NCT06182774: A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
  • The standard of care for individuals with myeloma who are not having a stem cell transplant is a treatment which includes the combination of drugs until they are no longer effective or cause major side effects. This study will assess whether a shorter duration of treatment for one of the drugs, daratumumab is as effective as continuous treatment.

  PR.26 (TRIPLE SWITCH)

  • TRIPLE-SWITCH: Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  • This study will assess whether adding Docetaxel chemotherapy to standard of care Androgen Deprivation Therapy (ADT) plus Androgen-Receptor Pathway Inhibitor (ARPI) is better or worse than the usual care for prostate cancer.
• Statins

  SAVER

  SAVER: Statins for Venous Event Reduction in Patients With Venous Thromboembolism

  This study aims to treat recurrent blood clots and post-thrombotic syndrome with the addition of a statin to regular anticoagulation therapy.

Studies Closed for Recruitment, Patients in Follow-Up

• Anticoagulants and antithrombotics

  Librexia-ACS

  • LIBREXIA-ACS: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (ACS)
  • 3 participants enrolled
• Anti-inflammatory drugs

  ARTEMIS

  • ARTEMIS: A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
  • 6 participants enrolled
• Oncology drugs

  BATTMAN

  • BATTMAN: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
  • 2 participants enrolled

  CO.29 (DYNAMIC III)

  • DYNAMIC-III: Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study
  • 13 participants enrolled

  MA.37 (PALLAS)

  • PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant along for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
  • 6 participants enrolled

  NCT01150045

  • NCT01150045: A Phase III Trial of 6 versus 12 Treatment of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer
  • 10 participants enrolled

  NCT02273375

  • NCT02273375: A Phase III Prospective Double-Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
  • 1 participant enrolled

  NCT02879318

  • NCT02879318: A Randomized Phase II Trial of Gemcitabine and Nab-Paxlitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
  • 5 participants enrolled

  POLARGO

  • POLARGO: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX Along in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • 1 participant enrolled

  PROSPECT

  • PROSPECT: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
  • 6 participants enrolled

  SORENTO

  • SORENTO: A randomized, multi-center, open-label, active-controlled phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors
  • 1 participant enrolled

  TAILOR

  • TAILOR: Multicohort Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
  • 5 participants enrolled

  TRANSFORM-1

  • TRANSFORM-1: Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
  • 1 participant enrolled

  VIKTORIA-1

  • VIKTORIA-1: Gedatolisib Plus Fulvestrant with or Without Palbociclib vs Standard-of-Care for the Treatment of Patients with Advanced or Metastatic HR+/HER2- Breast Cancer
  • 4 participants enrolled

Completed Studies

• Antibiotics

  BALANCE

  • BALANCE: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Randomized Controlled Clinical Trial
  • 86 participants enrolled

  SuDDICU

  • SuDDICU: A crossover, cluster randomised controlled trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit patients
  • 218 participants enrolled
• Anticoagulants and antithrombotics

  ANT-007 (ASTER)

  • ASTER: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
  • 8 participants enrolled

  ANT-008 (MAGNOLIA)

  • MAGNOLIA: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

  COACHeD

  • COACHeD: Improving Anticoagulant Safety at Hospital Discharge: A Pilot Randomized Trial - Coordination of Oral Anticoagulant Care at Hospital Discharge

  ENRICH-AF

  • ENRICH-AF: EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation
  • 3 participants enrolled

  EPCAT III

  • EPCATIII: Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban and Aspirin to Aspirin Alone Following Total Hip and Knee Arthroplasty
  • 332 participants enrolled

  HALO

  • HALO: Heparin Anticoagulation to improve Outcomes in septic shock: The HALO International Phase II RCT
  • 5 participants enrolled

  Librexia-STROKE

  • LIBREXIA-STROKE: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
  • 4 participants enrolled

  OCEANIC-AF

  • Assessing the Effect of Asundexian on Thrombotic Status, in Particular Endogenous Fibrinolysis, in Patients With Atrial Fibrillation
  • 8 participants enrolled
• Anti-inflammatory drugs

  ACT 2

  • ACT 2: Anti-Coronavirus Therapies (ACT) to prevent progression of COVID-19
  • 10 participants enrolled

  CATCO

  • CATCO: Canadian Arm of the SOLIDARITY Trial (Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Participants)
  • 34 participants enrolled

  CIAO

  • CIAO: COVID-19 Immunologic Antiviral therapy with Omalizumab
  • 2 participants enrolled

  CLEAR SYNERGY (OASIS 9)

  • A 2x2 factorial randomized controlled trial of CoLchicine and spironolactonE in patients with myocARdial infarction/SYNERGY Stent Registry – Organization to Assess Strategies for Ischemic Syndromes 9
  • 40 participants enrolled

  CONCOR-1

  • CONCOR-1: CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness
  • 13 participants enrolled

  LOVIT-COVID

  • LOVIT-COVID: Examining the effect of high-dose Vitamin C on mortality or organ damage in patients affected by COVID-19
  • 28 participants enrolled
• Cardiovascular biologics

  AEGIS-II

  • A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome
  • 16 participants enrolled
• Oncology drugs

  ALLTO

  • ALLTO: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer
  • 1 participant enrolled

  APHINITY

  • APHINITY: A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
  • 1 participant enrolled

  BRC.7 (INSIGNA)

  • INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis
  • 2 participants enrolled

  BL.5

  • BL.5: A Phase III Study of Primary Chemotherapy in Locally Advanced Transitional Cell Carcinoma of the Bladder
  • 3 participants enrolled

  BOLERO-2

  • BOLERO-2: Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

  CL.1

  • CL.1: A Phase III Comparison of Fludarabine Phosphate (NSC #312887) vs Chlorambucil vs Fludarabine Phosphate + Chlorambucil in Previously Untreated B-Cell Chronic Lymphocytic Leukemia
  • 5 participants enrolled

  CO.6

  • CO.6: Intergroup Rectal Adjuvant Protocol: A Phase III Study
  • 25 participants enrolled

  CO.7

  • CO.7: Phase III Clinical Trial of Chemotherapy with 5-Fluorouracil and L-leucovorin Following Potentially Curative Resection of Liver or Lung Metastases from Colorectal Cancer
  • 1 participant enrolled

  CO.9

  • CO.9: A Phase III Evaluation of High-Dose Levamisole Plus 5FU and Leucovorin as Surgical Adjuvant Therapy for High Risk Colon Cancer
  • 19 participants enrolled  

  HD.5

  • HD.5: Treatment of Advanced Hodgkin’s Disease a Randomized Phase III Trial Comparing ABVD versus MOPP/ABV Hybrid
  • 5 participants enrolled

  HORIZON II

  • HORIZON III: First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

  KEYNOTE 564

  • KEYNOTE-564: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy
  • 1 participant enrolled

  MA.11

  • MA.11: A Phase I Study of Escalating Epirubicin and Cyclophosphamide in Combination with 5-FU Using Granulocyte Colony Stimulating Factor Support in Premenopausal Women With Axillary Node Positive Operable Breast Cancer
  • 10 participants enrolled

  ME.8

  • ME.8: A Double-Blind, Placebo-controlled, Randomized Phase III Study Comparing the Complete and Partial Response Rates of a Combination of Carmustine (BCNU), Dacarbazine (DTIC) and Cisplatin With and Without Tamoxifen in Patients with Metastatic Melanoma

  MY.4

  • MY.4: Etidronate Disodium (EHDP) Versus Placebo in the Treatment of Multiple Myeloma
  • 1 participant enrolled

  MY.45

  • MY.5: Modified VAD (m-VAD-VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) in Primary Refractory and Relapsed Plasma Cell Myeloma
  • 1 participant enrolled

  MY.46

  • MY.46: Clinical Trial of Interferon versus no Additional Treatment in Multiple Myeloma Patients Who Have Responded to Melphalan and Prednisone
  • 14 participants enrolled

  MYSTIC

  • MYSTIC: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)
  • 3 participants enrolled

  NCT00002542

  • NCT00002542: Tamoxifen in Treating Women With High-Risk Breast Cancer

  NCT00002570

  • NCT00002570: A  Phase III Study of Immediate Versus Delayed Chemotherapy for Asymptomatic Advanced Colorectal Cancer
  • 11 participants enrolled

  NCT00002583

  • NCT00002583: Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed

  NCT00002678

  • NCT00002678: Combination Chemotherapy in Treating Patients with Multiple Myeloma

  NCT00002864

  • NCT00002864: Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

  NCT00002878

  • NCT00002878: Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
  • 2 participants enrolled

  NCT00003011

  • NCT00003011: A Phase III Study of Marimastat in Patients with Small Cell Lung Cancer Following a Response to First Line Chemotherapy
  • 6 participants enrolled

  NCT00003032

  • NCT00003032: High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

  NCT00003140

  • NCT00003140: Letrozole After Tamoxifen in Treating Women With Breast Cancer

  NCT00003653

  • NCT00003653: Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

  NCT00003892

  • NCT00003892: ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

  NCT00004179

  • NCT00004179: Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

  NCT00004934

  • NCT00004934: A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer
  • 2 participants enrolled

  NCT00006229

  • NCT00006229: Paclitaxel + Carboplatin With/​ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

  NCT00006890

  • NCT00006890: Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

  NCT00014222

  • NCT00014222: Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

  NCT00026338

  • NCT00026338: Gemcitabine With/​Out Erlotinib in Unresectable Locally Advanced/​Metastatic Pancreatic Cancer

  NCT00028743

  • NCT00028743: Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

  NCT00045032 (HERA)

  • NCT00045032: Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)

  NCT00049075

  • NCT00049075: A Phase II Study of Oral Fludarabine Phosphate in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
  • 2 participants enrolled

  NCT00056446

  • NCT00056446: Study of Oxaliplatin/​5-FU/​Leucovorin Plus Vatalanib Versus Oxaliplatin/​5-FU/​Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

  NCT00066313

  • NCT00066313: A Phase II Study Of ZD6474 Or Placebo In Small Cell Lung Cancer Patients Who Have Complete Or Partial Response To Induction Chemotherapy +/- Radiation Therapy
  • 7 participants enrolled

  NCT00066573

  • NCT00066573: Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

  NCT00079066

  • NCT00079066: A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma

  NCT00245154

  • NCT00245154: Paclitaxel + Carboplatin With/​Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

  NCT00265850

  • NCT00265850: Cetuximab and/ or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

  NCT00640471

  • NCT00640471: Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

  NCT00667251

  • NCT00667251: Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/​Neu-Positive Metastatic Breast Cancer

  NCT00754845

  • NCT00754845: Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy

  NCT00795340

  • NCT00795340: Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

  NCT01000025

  • NCT01000025: PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

  NCT01101438

  • NCT01101438: A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
  • 36 participants enrolled

  NCT01526135

  • NCT01526135: Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
  • 4 participants enrolled

  NCT02630693

  • NCT02630693: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
  • 4 participants enrolled

  NCT03057106

  • NCT03057106: A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • 3 participants enrolled

  OV.9

  • OV.9: A Multicentre, Randomized Comparative Study of Taxol in Platinum Treated Ovarian Cancer (High vs. Low Dose; Long vs. Short Infusion)
  • 1 participant enrolled

  OV.11

  • OV.11: A Phase II Trial of Intraperitoneal Cisplatin and Intravenous and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian Cancer
  • 1 participant enrolled

  OV.12

  • OV.12: A Phase III Comparison of BAY 12-9566 versus Placebo as Consolidation After Standard Chemotherapy in Patients with Epithelial Ovarian Cancer
  • 4 participants enrolled

  PA.1

  • PA.1: A Phase III Study of Bay 12-9566 Versus Gemcitabine in Patients with Advanced or Metastatic Adenocarcinoma of the Pancreas
  • 2 participants enrolled

  PALOMA-3

  • PALOMA-3: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure
• SGLT2 inhibitors

  DaNGER

  • DaNGER: Diabetic Ketoacidosis from New Use of an SGLT2
  • 8 participants enrolled